RT Journal Article
SR Electronic
T1 Early transmission dynamics of COVID-19 in Chile: From sub-exponential ascending growth dynamics to a stationary disease wave, March-April, 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.15.20103069
DO 10.1101/2020.05.15.20103069
A1 Tariq, Amna
A1 Undurraga, Eduardo A.
A1 Castillo Laborde, Carla
A1 Vogt-Geisse, Katia
A1 Luo, Ruiyan
A1 Rothenberg, Richard
A1 Chowell, Gerardo
YR 2020
UL http://medrxiv.org/content/early/2020/05/18/2020.05.15.20103069.abstract
AB The COVID-19 pandemic reached Latin America in February 2020, with the first case in Chile identified on March 3rd, 2020. Since then Chile has accumulated a total of 14365 cases as of April 28th, 2020. We estimate the reproduction number during the early transmission phase in Chile and study the effectiveness of control interventions by conducting short-term forecasts based on early transmission dynamics of COVID-19. The incidence curve displays sub-exponential growth dynamics with the scaling of growth parameter, p, estimated at 0.8 (95% CI: 0.7, 0.8) and the reproduction number estimated at 1.6 (95% CI: 1.5, 1.6). The sub-epidemic model indicates a stationary wave of stable epidemic size. Our current findings point to sustained transmission of SARS-CoV-2 in Chile. While the social distancing interventions have slowed the virus spread, the number of new COVID-19 cases continue to accrue, underscoring the need for persistent social distancing efforts to control the epidemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding has been reported.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are publicly available.